Summary
No FDA label excerpts for dosing/administration, indications for Sustenna, contraindications, or safety beyond dementia-related psychosis were provided. The listed statements also include multiple claims not supported by the supplied label excerpts, so overall alignment cannot be verified.
Category Scores
Accurate Statements
Invega Sustenna is manufactured by Janssen Pharmaceuticals.
Not supported or refuted by the provided FDA label excerpts (only dementia-related psychosis warnings for INVEGA are included).
Unsupported Statements
Invega Sustenna is a long-acting injectable antipsychotic.
The provided FDA label excerpts do not contain information about Invega Sustenna formulation or indication.
Invega Sustenna is administered intramuscularly.
No label excerpt provided for administration route of Invega Sustenna.
The initial dose of Invega Sustenna is 234 mg given on day 1 of treatment.
No dose regimen for Invega Sustenna was provided in the supplied excerpts.
The initial dose is followed by a second dose of 156 mg approximately one week later.
No dose regimen for Invega Sustenna was provided in the supplied excerpts.
After initial titration, maintenance doses can range from 39 mg to 234 mg every four weeks.
No maintenance dosing details for Invega Sustenna were provided in the supplied excerpts.
Maintenance dosing depends on what is tolerated and effective for the patient.
No maintenance dosing guidance was provided in the supplied excerpts.
Invega Sustenna injection volume varies with the dose, ranging from 0.5 mL to 2.5 mL.
No injection volume information was provided in the supplied excerpts.
Invega Sustenna is paliperidone palmitate.
The provided excerpts discuss INVEGA (paliperidone) in dementia-related psychosis and do not describe Sustenna’s chemical form.
Invega Sustenna is designed for monthly administration.
No administration frequency details were provided in the supplied excerpts.
Invega is oral paliperidone taken daily.
Provided excerpts are about INVEGA dementia-related psychosis warnings and do not include dosing form/frequency details.
Invega Sustenna is the active metabolite of risperidone.
The provided excerpts do not support this biochemical relationship; only paliperidone is mentioned.
Patients can be switched from oral Invega to Invega Sustenna.
No switching/conversion guidance was provided in the supplied excerpts.
The specific conversion strategy for switching depends on the dosage of oral Invega and the desired starting dose of Invega Sustenna.
No switching/conversion guidance was provided in the supplied excerpts.
Common side effects of Invega Sustenna can include weight gain.
No adverse reaction list for Invega Sustenna is provided in the supplied excerpts.
Common side effects of Invega Sustenna can include somnolence.
No adverse reaction list for Invega Sustenna is provided in the supplied excerpts.
Common side effects of Invega Sustenna can include akathisia.
No adverse reaction list for Invega Sustenna is provided in the supplied excerpts.
Invega Sustenna is used for treatment of schizophrenia in adults.
No indication language for Invega Sustenna was provided in the supplied excerpts.
Invega Sustenna is used for treatment of schizoaffective disorder in adults.
No indication language for Invega Sustenna was provided in the supplied excerpts.
Information regarding specific patent expiry dates for Invega Sustenna is available through specialized patent databases.
The provided FDA excerpts do not address patent expiry information; this is not contained in the label excerpts.
Contradictions
Important Omissions
Boxed warning content specifically applicable to Invega Sustenna (paliperidone palmitate) beyond the dementia-related psychosis excerpts; contraindications; detailed warnings/precautions; drug interactions; monitoring; and complete adverse reaction profile for Invega Sustenna.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Because the response contains many dosing/administration/indication and adverse-effect claims that are not supported by the supplied FDA label excerpts, label-alignment cannot be verified. If any of these claims were incorrect for Invega Sustenna, it could lead to substantial clinical risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major elements (indications, dosing, administration, adverse reactions, and Sustenna-specific formulation details) are not supported by the FDA label excerpts provided in the prompt; therefore compliance cannot be confirmed.
Suggested Improvement
Provide FDA label excerpts for Invega Sustenna (not just INVEGA dementia-related psychosis warnings) covering: boxed warnings, indications, dosing/administration, contraindications, warnings/precautions, drug interactions, adverse reactions, and monitoring. Then re-evaluate each statement against those specific sections.